4mqu: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Human GKRP complexed to AMG-3969 and S6P== | ==Human GKRP complexed to AMG-3969 and S6P== | ||
<StructureSection load='4mqu' size='340' side='right' caption='[[4mqu]], [[Resolution|resolution]] 2.22Å' scene=''> | <StructureSection load='4mqu' size='340' side='right' caption='[[4mqu]], [[Resolution|resolution]] 2.22Å' scene=''> | ||
| Line 5: | Line 6: | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=IOD:IODIDE+ION'>IOD</scene>, <scene name='pdbligand=MG9:2-{4-[(2S)-4-[(6-AMINOPYRIDIN-3-YL)SULFONYL]-2-(PROP-1-YN-1-YL)PIPERAZIN-1-YL]PHENYL}-1,1,1,3,3,3-HEXAFLUOROPROPAN-2-OL'>MG9</scene>, <scene name='pdbligand=S6P:D-SORBITOL-6-PHOSPHATE'>S6P</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=IOD:IODIDE+ION'>IOD</scene>, <scene name='pdbligand=MG9:2-{4-[(2S)-4-[(6-AMINOPYRIDIN-3-YL)SULFONYL]-2-(PROP-1-YN-1-YL)PIPERAZIN-1-YL]PHENYL}-1,1,1,3,3,3-HEXAFLUOROPROPAN-2-OL'>MG9</scene>, <scene name='pdbligand=S6P:D-SORBITOL-6-PHOSPHATE'>S6P</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | ||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4mro|4mro]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4mro|4mro]]</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4mqu FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4mqu OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4mqu RCSB], [http://www.ebi.ac.uk/pdbsum/4mqu PDBsum]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4mqu FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4mqu OCA], [http://pdbe.org/4mqu PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4mqu RCSB], [http://www.ebi.ac.uk/pdbsum/4mqu PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4mqu ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Function == | == Function == | ||
| Line 17: | Line 18: | ||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
</div> | </div> | ||
<div class="pdbe-citations 4mqu" style="background-color:#fffaf0;"></div> | |||
==See Also== | |||
*[[Glucokinase Regulatory Protein|Glucokinase Regulatory Protein]] | |||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 17:24, 4 August 2016
Human GKRP complexed to AMG-3969 and S6PHuman GKRP complexed to AMG-3969 and S6P
Structural highlights
Function[GCKR_HUMAN] Inhibits glucokinase by forming an inactive complex with this enzyme. Publication Abstract from PubMedIn the previous report , we described the discovery and optimization of novel small molecule disruptors of the GK-GKRP interaction culminating in the identification of 1 (AMG-1694). Although this analogue possessed excellent in vitro potency and was a useful tool compound in initial proof-of-concept experiments, high metabolic turnover limited its advancement. Guided by a combination of metabolite identification and structure-based design, we have successfully discovered a potent and metabolically stable GK-GKRP disruptor (27, AMG-3969). When administered to db/db mice, this compound demonstrated a robust pharmacodynamic response (GK translocation) as well as statistically significant dose-dependent reductions in fed blood glucose levels. Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 2. Leveraging structure-based drug design to identify analogues with improved pharmacokinetic profiles.,St Jean DJ Jr, Ashton KS, Bartberger MD, Chen J, Chmait S, Cupples R, Galbreath E, Helmering J, Hong FT, Jordan SR, Liu L, Kunz RK, Michelsen K, Nishimura N, Pennington LD, Poon SF, Reid D, Sivits G, Stec MM, Tadesse S, Tamayo N, Van G, Yang KC, Zhang J, Norman MH, Fotsch C, Lloyd DJ, Hale C J Med Chem. 2014 Jan 23;57(2):325-38. doi: 10.1021/jm4016747. Epub 2014 Jan 9. PMID:24405213[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||